Drug Discovery

#Biotechnology #Cell and gene therapy #Covid-19 #Drug delivery #Drug development #Drug technology #Immunology / Virology & Vaccines

Antibody therapeutics: the other race for immunity against SARS-CoV2

Sophie Lutter, OXGENE, looks at the important role antibody therapeutics have to play and how, as the world has looked for Covid-19 treatments in the last year, their significance has been noted. As the world continues to adjust and respond to the impact of the Covid-19 pandemic, the race… Read More

#Covid-19 #Exclusive Content #News

#Cell and gene therapy #Clinical research #Drug development

Update on gene therapy trial where patient suffered loss of vision

Adverum Biotechnologies has announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its Infinity clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomisation in one patient treated with a single intravitreal… Read More

#News

#Assay #Drug development #Drug toxicity #Preclinical development #Toxicology

Enhancing the predictability of drug toxicity and efficacy

There is an unmet clinical need in drug development for in vitro models that reduce the risk of drug-induced toxicity and late-stage drug attrition. In this webinar, hosted on May 26 2021, two expert speakers discuss how researchers can enhance the predictability of pre-clinical drug development. This webinar, Enhancing the predictability of… Read More

#Editor's Choice #News

#Drug discovery #Proteogenomics #Sitting Down With

The importance of proteogenomics in drug discovery

The latest DDW Sponsored Sitting Down With podcast features Anders Mälarstig, Director of Human Genetics, Pfizer. In this podcast he outlines the role of pQTLs in the drug discovery process and the growing importance of proteogenomics Mälarstig  is currently responsible for developing and applying strategies for new drug targets and… Read More

#Podcasts

#Antibodies #Cell therapy #DNA #Drug delivery #Drug development #Drug discovery #Sequencing

Accelerating antibody discovery by making sequence space accessible

The biggest constraint in discovering new antibodies for immunotherapy is constructing the underlying DNA sequence, says Dr. Aaron Sato, CSO of Twist Bioscience. Inside the human body, the immune system generates antibodies that can target just about any foreign molecule. It does so through DNA recombination and somatic hypermutation –… Read More

#Editor's Choice #Exclusive Content #News

#Biopharmaceuticals #Drug development #Life sciences

Awakn Life Sciences and Evotec start chemical entity programme

Awakn Life Sciences, a biotechnology company focused on addiction, has initiated a new chemical entity (NCE) development programme to strengthen its pipeline for the treatment of a broad range of addictions. The company has also announced the appointment of Evotec as its NCE research partner and the selection of… Read More

#News

#Corning Life Sciences #Drug delivery #Drug development #Drug discovery #Gene therapy #Genetics #Genetics / genomes #Life sciences #Research

Process Development in Gene Therapy: Four Things to Know

By John Yoshi Shyu, Ph.D. Corning Life Sciences. Gene therapy – the addition, deletion, or modification of genes in living organisms – has been around, at least in concept, since the 1980s. Gene modification or editing incorporates two main strategies: insertion of novel genetic constructs into existing genes, and gene… Read More

#Exclusive Content #News

#Drug discovery #Podcast #Proteogenomics

The importance of proteogenomics in drug discovery: podcast

The latest DDW Sitting Down With podcast features Anders Mälarstig, Director of Human Genetics, Pfizer. In this podcast he outlines the role of pQTLs in the drug discovery process and the growing importance of proteogenomics Mälarstig  is currently responsible for developing and applying strategies for new drug targets and precision… Read More

#Editor's Choice #News

#Covid-19 #Data #Drug delivery #Drug development #Drug discovery #Research

Interim data suggests drug may prevent cytokine storm

Clinical-stage drug development company Noxopharm has announced that in a cohort of 18 patients with moderately severe cases of Covid-19, interim data from its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with the worsening of the virus. “Until enough people are vaccinated to achieve… Read More

#News

#Clinical trial #Drug design #Drug development #Drug discovery #Research

Call to rethink “primitive” clinical trial approaches

Virtual clinical development specialist, Phesi, is calling for clinical trials to be designed using industry modal values (data values that appear most often in historical trials data) to reduce protocol amendments. Phesi analysed 330,000 clinical trials from the past 15 years and found the majority require substantial protocol amendments and… Read More

#News

#Clinical trials #Depression #Drug development #GlobalData

Novel antidepressant has blockbuster potential

Following the news that the Food and Drug Administration (FDA) has accepted Axsome Therapeutics’ new drug application (NDA) for its novel antidepressant therapy AXS-05 and granted it priority review, GlobalData commented that it would be “a blockbuster drug” by 2026, estimating global sales of approximately US$1.3 billion by 2029. Philippa… Read More

#News #Trending News

#Diabetes #Drug development #Drug discovery #Type 2 diabetes

Muscle gene linked to Type 2 diabetes

Research published in Nature Communications by a team from Lund University in Sweden has discovered that in Type 2 diabetes, a specific gene influences muscle stem cells’ ability to create new mature muscle cells. “In people with Type 2 diabetes, the VPS39 gene is significantly less active in the muscle… Read More

#News

#Biopharmaceuticals #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug innovation #Immunology / Virology & Vaccines #Pharma #Pharmaceuticals #Vaccines

Integration at its best: Dalton Pharma outlines its CDMO expertise

Dalton Pharma Services, a contract development and manufacturing organisation (CDMO) offers expertise in drug discovery, formulation and process development, custom synthesis, and GMP manufacturing services. Lu Rahman spoke to CEO, Peter Pekos about the company’s ongoing expertise. LR: The company has experience supplying the needs of the orphan drug field… Read More

#Exclusive Content #News #Opinion

#AI #AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biopharmaceuticals #Drug delivery #Drug development #Drug discovery

Putting the power into drug design: the important role of AI

Valence’s co-founder and CEO, Daniel Cohen, spoke to Lu Rahman about the company’s plan to empower drug discovery scientists with AI-enabled drug design LR:  Outline of the company and its main initiatives DC: Valence is an interdisciplinary team of scientists and engineers out of Mila, the world’s largest deep learning… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Clinical trial #Drug development #Drug discovery

MHRA authorises treatment to reduce the risk of cardiovascular events

Amarin Corporation has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a Great Britain Marketing Authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce the risk of cardiovascular events in high cardiovascular risk statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and either established… Read More

#News